Literature DB >> 16369233

Disseminated aspergillosis following infliximab therapy in an immunosuppressed patient with Crohn's disease and chronic hepatitis C: a case study and review of the literature.

Joel W Alderson1, Thomas G Van Dinter, Michael J Opatowsky, Elizabeth C Burton.   

Abstract

A 55-year-old white woman with a greater than 25-year history of Crohn's disease developed disseminated aspergillosis following combination therapy with Methylprednisolone, azathioprine, and infliximab. The patient was hospitalized 11 days after initiation of infliximab for respiratory symptoms and developed respiratory failure, coma, and died. Postmortem examination revealed disseminated Aspergillus fumigatus involving multiple organs. This case demonstrates that combined treatment with infliximab, methylprednisone, and azathioprine may induce severe immunosuppression and depressed cellular immunity, leading to severe opportunistic infections. Given the increasing use of antitumor necrosis factor agents, physicians should be aware of the risk of opportunistic infections and be vigilant about diagnosing and aggressively treating these infections to reduce the risk of disseminated disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16369233      PMCID: PMC1681636     

Source DB:  PubMed          Journal:  MedGenMed        ISSN: 1531-0132


  40 in total

1.  Invasive pulmonary aspergillosis associated with infliximab therapy.

Authors:  A Warris; A Bjørneklett; P Gaustad
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

2.  Refinements of environmental assessment during an outbreak investigation of invasive aspergillosis in a leukemia and bone marrow transplant unit.

Authors:  C L Thio; D Smith; W G Merz; A J Streifel; G Bova; L Gay; C B Miller; T M Perl
Journal:  Infect Control Hosp Epidemiol       Date:  2000-01       Impact factor: 3.254

Review 3.  The clinical spectrum of pulmonary aspergillosis.

Authors:  Ayman O Soubani; Pranatharthi H Chandrasekar
Journal:  Chest       Date:  2002-06       Impact factor: 9.410

4.  Shingles following infliximab infusion.

Authors:  D C Baumgart; A U Dignass
Journal:  Ann Rheum Dis       Date:  2002-07       Impact factor: 19.103

5.  Central nervous system aspergillosis: a 20-year retrospective series.

Authors:  B K Kleinschmidt-DeMasters
Journal:  Hum Pathol       Date:  2002-01       Impact factor: 3.466

6.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

Authors:  J Keane; S Gershon; R P Wise; E Mirabile-Levens; J Kasznica; W D Schwieterman; J N Siegel; M M Braun
Journal:  N Engl J Med       Date:  2001-10-11       Impact factor: 91.245

7.  Efficacy of prevention by high-efficiency particulate air filtration or laminar airflow against Aspergillus airborne contamination during hospital renovation.

Authors:  M Cornet; V Levy; L Fleury; J Lortholary; S Barquins; M H Coureul; E Deliere; R Zittoun; G Brücker; A Bouvet
Journal:  Infect Control Hosp Epidemiol       Date:  1999-07       Impact factor: 3.254

Review 8.  Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: overview of randomized clinical studies.

Authors:  Stephen B Hanauer
Journal:  Rev Gastroenterol Disord       Date:  2004

9.  Disseminated aspergillosis inciting intestinal ischaemia and obstruction.

Authors:  S S Shah; B A Birnbaum; J E Jacobs
Journal:  Br J Radiol       Date:  2001-12       Impact factor: 3.039

Review 10.  A model to predict survival in patients with end-stage liver disease.

Authors:  P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

View more
  11 in total

1.  Expression of immunomodulatory genes in human monocytes induced by voriconazole in the presence of Aspergillus fumigatus.

Authors:  M Simitsopoulou; E Roilides; C Likartsis; J Ioannidis; A Orfanou; F Paliogianni; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2006-12-18       Impact factor: 5.191

2.  Complications of tumor necrosis factor-α blockade in chronic granulomatous disease-related colitis.

Authors:  Gulbu Uzel; Jordan S Orange; Nina Poliak; Beatriz E Marciano; Theo Heller; Steven M Holland
Journal:  Clin Infect Dis       Date:  2010-11-08       Impact factor: 9.079

3.  Disseminated aspergillosis causing intestinal failure following colectomy for perforated colitis.

Authors:  Kevin McElvanna; Maurice B Loughrey; Scott Gillespie; Keith R Gardiner
Journal:  Frontline Gastroenterol       Date:  2014-07-23

4.  Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study.

Authors:  John W Baddley; Kevin L Winthrop; Lang Chen; Liyan Liu; Carlos G Grijalva; Elizabeth Delzell; Timothy Beukelman; Nivedita M Patkar; Fenglong Xie; Kenneth G Saag; Lisa J Herrinton; Daniel H Solomon; James D Lewis; Jeffrey R Curtis
Journal:  Ann Rheum Dis       Date:  2013-07-13       Impact factor: 19.103

Review 5.  The influence of anti-TNF therapy on the course of chronic hepatitis C virus infection in patients with inflammatory bowel disease.

Authors:  Ming Valerie Lin; Wojciech Blonski; Anna M Buchner; K Rajender Reddy; Gary R Lichtenstein
Journal:  Dig Dis Sci       Date:  2012-11-20       Impact factor: 3.199

6.  Epidemiology and treatment approaches in management of invasive fungal infections.

Authors:  Jane Kriengkauykiat; James I Ito; Sanjeet S Dadwal
Journal:  Clin Epidemiol       Date:  2011-05-19       Impact factor: 4.790

7.  Infliximab in the treatment of Crohn's disease.

Authors:  Gilberto Poggioli; Silvio Laureti; Massimo Campieri; Filippo Pierangeli; Paolo Gionchetti; Federica Ugolini; Lorenzo Gentilini; Piero Bazzi; Fernando Rizzello; Maurizio Coscia
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423

8.  Granulomatous response to invasive pulmonary aspergillosis in an immunotherapy-naive host, a maladaptive response?

Authors:  Andres L Mora Carpio; Jessica M Stempel; Daniela de Lima Corvino; Veronica Garvia; Antonette Climaco
Journal:  Respir Med Case Rep       Date:  2018-05-16

9.  Disseminated Aspergillosis due to Aspergillus niger in Immunocompetent Patient: A Case Report.

Authors:  Ulku Ergene; Zeynep Akcali; Demircan Ozbalci; Nalan Nese; Sebnem Senol
Journal:  Case Rep Infect Dis       Date:  2013-02-28

10.  Mucormycosis in patients with inflammatory bowel disease: case series and review of the literature.

Authors:  Maheen Z Abidi; Nayantara Coelho-Prabhu; James Hargreaves; Tim Weiland; Irminne Van Dyken; Aaron Tande; Pritish K Tosh; Randall C Walker; Nathan W Cummins
Journal:  Case Rep Med       Date:  2014-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.